Product Name

  • Name

    Grepafloxacin hydrochloride

  • EINECS
  • CAS No. 161967-81-3
  • Density
  • Solubility
  • Melting Point
  • Formula C19H22FN3O3.HCl
  • Boiling Point 626.7 °C at 760 mmHg
  • Molecular Weight 395.86
  • Flash Point 332.8 °C
  • Transport Information
  • Appearance
  • Safety
  • Risk Codes
  • Molecular Structure Molecular Structure of 161967-81-3 (Grepafloxacin hydrochloride)
  • Hazard Symbols
  • Synonyms 3-Quinolinecarboxylicacid,1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-,monohydrochloride (9CI);3-Quinolinecarboxylic acid,1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-,monohydrochloride, (?à)-;Grepafloxacin hydrochloride;OPC 17116;Raxar;Vaxar;dl-Grepafloxacinhydrochloride;
  • PSA 74.57000
  • LogP 3.47600

Grepafloxacin hydrochloride Specification

The Grepafloxacin hydrochloride with the CAS number 161967-81-3 is also called 3-Quinolinecarboxylicacid,1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-,hydrochloride (1:1). The IUPAC name is 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid hydrochloride. Its molecular formula is C19H22FN3O3.HCl.

The properties of the chemical are: (1)ACD/LogP: 1.61; (2)# of Rule of 5 Violations: 0; (3)#H bond acceptors: 6; (4)#H bond donors: 2; (5)#Freely Rotating Bonds: 3; (6)Polar Surface Area: 53.09 Å2; (7)Flash Point: 332.8 °C; (8)Enthalpy of Vaporization: 97.51 kJ/mol; (9)Boiling Point: 626.7 °C at 760 mmHg; (10)Vapour Pressure: 1.43×10-16 mmHg at 25°C.

Uses: This chemical can react with methanol to prepare 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methyl ester. This reaction needs reagent SOCl2 at heating condition. The reaction time is 4.0 hours. The yield is 77%.

You can still convert the following datas into molecular structure:
(1)SMILES: Cl.O=C(O)\C2=C\N(c1cc(c(F)c(c1C2=O)C)N3CC(NCC3)C)C4CC4
(2)InChI: InChI=1/C19H22FN3O3.ClH/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12;/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26);1H
(3)InChIKey: IEPMBYOIQGCVHO-UHFFFAOYAR

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
monkey LD50 intravenous > 100mg/kg (100mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

GASTROINTESTINAL: NAUSEA OR VOMITING		 Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995.
monkey LD50 oral > 2gm/kg (2000mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

GASTROINTESTINAL: NAUSEA OR VOMITING		 Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995.
mouse LD50 intravenous 69200ug/kg (69.2mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"		 Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995.
mouse LD50 oral 3900mg/kg (3900mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR		 Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995.
mouse LD50 subcutaneous > 2gm/kg (2000mg/kg) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"		 Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995.
rat LD50 intravenous 152mg/kg (152mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"		 Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995.
rat LD50 oral 3029mg/kg (3029mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS		 Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995.
rat LD50 subcutaneous > 2gm/kg (2000mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"		 Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995.

Related Products

Hot Products

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View